다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
Basic and clinical andrology, v.29 no.1, 2019년, pp.3 -
Baetas, João (Laboratory of Cell Biology, Department of Microscopy, Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto (UP), Rua Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal) , Rabaça, Ana (Laboratory of Cell Biology, Department of Microscopy, Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto (UP), Rua Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal) , Gonçalves, Ana (Centre for Reproductive Genetics A. Barros (CGR), Av. do Bessa, 240, 1° Dto. Frente, 4100-012 Porto, Portugal) , Barros, Alberto (Centre for Reproductive Genetics A. Barros (CGR), Av. do Bessa, 240, 1° Dto. Frente, 4100-012 Porto, Portugal) , Sousa, Mário (Laboratory of Cell Biology, Department of Microscopy, Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto (UP), Rua Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal) , Sá, Rosália (Laboratory of Cell Biology, Department of Microscopy, Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto (UP), Rua Jorge Viterbo Ferreira, 228, 4050-313 Porto, Por)
AI-Helper
BackgroundAlthough recent progress in cancer treatment has increased patient survival and improved quality of life, reproductive side effects are still for concern. One way to decrease gonadal impairment is to use cytoprotectors. In testicular cancer, etoposide is generally used in combination with ...
RésuméContexteBien que les récents progrès dans le traitement des cancers aient augmenté la survie des patients et amélioré leur qualité de vie, les effets secondaires sur la reproduction restent encore des motifs d’inquiétude. Une façon de réduire les altérations gonadiques consiste en l’utilisation de cytoprotecteurs. Dans le cancer du testicule, l’étoposide est habituellement utilisée en association avec d’autres agents, mais il n’existe aucune étude in vitro de l’exposition des spermatozoïdes à l’étoposide et à des cytoprotecteurs, notamment la N-acétylcystéine (NAC).Matériel et MéthodesVingt échantillons de sperme ont été répartis en cinq groupes : témoins, incubés avec NAC seule, incubés avec étoposide seul, exposés séquentiellement à NAC puis à étoposide (pré traitement), et exposés séquentiellement à étoposide puis à NAC (post traitement). Les paramètres spermatiques, la condensation de la chromatine (bleu d’aniline), la fragmentation de l’ADN (TUNEL), le stress oxydatif (marquage OxyDNA) et la quantification du glutathion ont été utilisés pour évaluer les capacités de NAC comme agent prophylactique (pré traitement) ou comme améliorateur (post traitement) des effets causés sur les spermatozoïdes lors d’une exposition in vitro à l’étoposide.RésultatsAucun effet délétère n’a été observé sur la mobilité ou sur l’intégrité de la membrane des spermatozoïdes. Les résultats montrent que l’utilisation prophylactique (pré traitement) de NAC augmente les taux des spermatozoïdes avec chromatine immature en comparaison de l’utilisation amélioratrice (post traitement) de NAC, et augmente les taux de fragmentation de l’ADN des spermatozoïdes par rapport aux témoins. L’utilisation de NAC en pré et post traitement augmente les taux d’oxydation par rapport aux témoins, mais augmente aussi les taux de glutathion anti-oxydant cellulaire.ConclusionsLes résultats indiquent que NAC possède la capacité de contrebalancer la toxicité induite par l’étoposide plutôt que celle d’empêcher les effets cytotoxiques de l’étoposide sur l’ADN des spermatozoïdes ; ceci suggère que l’administration de NAC aux cellules préalablement exposées à l’étoposide est préférable à son utilisation prophylactique. Comme les résultats témoignent que NAC semble être plus efficace à atténuer les effets cytotoxiques de l’étoposide sur les spermatozoïdes plutôt que d’être utilisée comme agent chimio prophylactique, ceci renforce l’idée qu’il pourrait exister un nouveau mécanisme de NAC sur l’ADN.Mots-clésN-acétylcystéine (NAC), Etoposide, Fragmentation de l’ADN spermatique, Stress oxydatif spermatique
1. Albers P Albrecht W Algaba F Bokemeyer C Cohn-Cedemark G Fizazi K Guidelines on testicular cancer: 2015 update Eur Urol 2015 68 1054 1068 10.1016/j.eururo.2015.07.044 26297604
2. Calabrò F Albers P Bokemeyer C Martin C Einhorn LH Horwich A The contemporary role of chemotherapy for advanced testis cancer: a systematic review of the literature Eur Urol 2012 61 1212 1221 10.1016/j.eururo.2012.03.038 22464311
3. Fung C Fossa SD Williams A Travis LB Long-term morbidity of testicular cancer treatment Urol Clin North Am 2015 42 393 408 10.1016/j.ucl.2015.05.002 26216826
4. Cvancarova M Samuelsen SO Magelssen H Fossa SD Reproduction rates after cancer treatment: experience from the Norwegian radium hospital J Clin Oncol 2009 27 334 343 10.1200/JCO.2007.15.3130 19075285
5. Williams DH Karpman E Sander JC Spiess PE Pisters LL Lipshultz LI Pretreatment semen parameters in men with cancer J Urol 2009 181 736 740 10.1016/j.juro.2008.10.023 19091343
6. Rabaça A Sousa M Alves M Oliveira PF Sá R Novel drug therapies for fertility preservation in men undergoing chemotherapy: clinical relevance of protector agents Curr Med Chem 2015 22 3347 3369 10.2174/0929867322666150821094334 26295467
7. Chen AY Liu LF DNA topoisomerases: essential enzymes and lethal targets Ann Rev Pharmacol Toxicol 1994 34 191 218 10.1146/annurev.pa.34.040194.001203 8042851
8. Kelland L The resurgence of platinum-based cancer chemotherapy Nat Rev Cancer 2007 7 573 584 10.1038/nrc2167 17625587
9. Froelich-Ammon SJ Osheroff N Topoisomerase poisons: harnessing the dark side of enzyme mechanism J Biol Chem 1995 270 21429 21432 10.1074/jbc.270.37.21429 7665550
10. Auger J, Sermondade N, Eustache F. Semen quality of 4480 young cancer and systematic disease patients: baseline data and clinical considerations. Basic Clin Androl. 2016;26(3). 10.1186/s12610-016-0031-x.
11. Caponecchia L Cimino G Sacchetto R Fiori C Sebastianelli A Salacone P Do malignant diseases affetc semen quality? Sperm parameters of men with cancer Andrologia 2016 48 333 340 10.1111/and.12451 26173956
12. Santo L Siu KT Raje N Targeting cyclin-dependent kinases and cell cycle progression in human cancers Semin Oncol 2015 42 788 800 10.1053/j.seminoncol.2015.09.024 26615126
13. Reznikov A Hormonal impact on tumor growth and progression Exp Oncol 2015 37 162 172 26422099
14. Michot JM Bigenwald C Champiat S Collins M Carbonnel F Postel-Vinay S Immune-related adverse events with immune checkpoint blockade: a comprehensive review Eur J Cancer 2016 54 139 148 10.1016/j.ejca.2015.11.016 26765102
15. Fuchs-Tarlocsky V Role of antioxidants in cancer therapy Nutrition 2013 29 15 21 10.1016/j.nut.2012.02.014 22784609
16. Thyagarajan A Sahu RP Potential contributions of antioxidants to cancer therapy: immunomodulation and radiosensitization Integr Cancer Ther 2018 17 2010 2016 10.1177/1534735416681639
17. Drisko JA Chapman J Hunter VJ The use of antioxidant therapies during chemotherapy Gynecol Oncol 2003 88 434 439 10.1016/S0090-8258(02)00067-7 12648599
18. Aruoma OI Halliwell B Hoey BM Butler J The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid Free Rad Biol Med 1989 6 593 597 10.1016/0891-5849(89)90066-X 2546864
19. Bonanomi L Gazzaniga A Toxicological, pharmacokinetic and metabolic studies on acetylcysteine Eur J Respir Dis Suppl 1980 111 45 51 6938410
20. Johnston RE Hawkins HC Weikel JH Jr The toxicity of N-acetylcysteine in laboratory animals Semin Oncol 1983 10 1Suppl1 17 24 6682250
21. Cai T Fassina G Morini M Aluigi MG Masiello L Fontanini G N-acetylcysteine inhibits endothelial cell invasion and angiogenesis Lab Investig 1999 79 1151 1159 10496534
22. Agarwal A Virk G Ong C du Plessis SS Effect of oxidative stress on male reproduction World J mens Health 2014 32 1 17 10.5534/wjmh.2014.32.1.1
23. Bisht S Faiq M Tolahunase M Dada R Oxidative stress and male infertility Nat Rev Urol 2017 14 470 485 10.1038/nrurol.2017.69 28508879
24. Agarwal A Nallella KP Allamaneni SSR Said TM Role of antioxidants in treatment of male infertility: an overview of the literature Reprod BioMed Online 2004 8 616 627 10.1016/S1472-6483(10)61641-0 15169573
25. Ciftci H Verit A Savas M Yeni E Erel O Effects of N-acetylcysteine on semen parameters and oxidative/antioxidant status Urology 2009 74 73 76 10.1016/j.urology.2009.02.034 19428083
26. Kefer JC Agarwal A Sabanegh E Role of antioxidants in the treatment of male infertility Int J Urol 2009 16 449 457 10.1111/j.1442-2042.2009.02280.x 19383039
27. Stephenson W Poirier SM Rubin L Einhorn LH Evaluation of reproductive capacity in germ cell tumor patients following treatment with cisplatin, etoposide, and bleomycin J Clin Oncol 1995 13 2278 2280 10.1200/JCO.1995.13.9.2278 7545220
28. De Mas P Daudin M Vincent MC Bourrouillou G Calvas P Mieusset R Increased aneuploidy in spermatozoa from testicular tumour patients after chemotherapy with cisplatin, etoposide and bleomycin Hum Reprod 2001 16 1204 1208 10.1093/humrep/16.6.1204 11387293
29. Ghezzi M Berretta M Bottacin A Palego P Sartini B Cosci I Impact of Bep or carboplatin chemotherapy on testicular function and sperm nucleus of subjects with testicular germ cell tumor Front Pharmacol 2016 7 122 10.3389/fphar.2016.00122 27242529
30. Bagheri-Sereshki N Hales BF Robaire B The effects of chemotherapeutic agents, bleomycin, etoposide, and cisplatin, on chromatin remodeling in male rat germ cells Biol Reprod 2016 94 81 10.1095/biolreprod.115.137802 26911428
31. Russell LB Hunsicker PR Johnson DK Shelby MD Unlike other chemicals, etoposide (a topoisomerase-II inhibitor) produces peak mutagenicity in primary spermatocytes of the mouse Mutat Res 1998 400 279 286 10.1016/S0027-5107(98)00036-0 9685680
32. Russell LB Hunsicker PR Hack AM Ashley T Effect of the topoisomerase-II inhibitor etoposide on meiotic recombination in male mice Mutat Res 2000 464 201 212 10.1016/S1383-5718(99)00185-0 10648907
33. Matulis S Handel MA Spermatocyte responses in vitro to induced DNA damage Mol Reprod Dev 2006 73 1061 1072 10.1002/mrd.20508 16700071
34. Marchetti F Pearson FS Bishop JB Wyrobek AJ Etoposide induces chromosomal abnormalities in mouse spermatocytes and stem cell spermatogonia Hum Reprod 2006 21 888 895 10.1093/humrep/dei416 16311288
35. Okada FK Stumpp T Miraglia SM Carnitine reduces testicular damage in rats treated with etoposide in the prepubertal phase Cell Tiss Res 2009 337 269 280 10.1007/s00441-009-0801-2
36. Reddy KP Madhu P Reddy PS Protective effects of resveratrol against cisplatin-induced testicular and epididymal toxicity in rats Food Chem Toxicol 2016 91 65 72 10.1016/j.fct.2016.02.017 26925769
37. Afsar T Razak S Khan MR Almajwal A Acacia hydaspica ethyl acetate extract protects against cisplatin-induced DNA damage, oxidative stress and testicular injuries in adult male rats BMC Cancer 2017 17 883 10.1186/s12885-017-3898-9 29268699
38. World Health Organization (WHO) WHO laboratory manual for the examination and processing of human semen 2010 Geneva WHO Press
39. Charan J Kantharia ND How to calculate sample size in animal studies? J Pharmacol Pharmacother 2013 4 303 306 10.4103/0976-500X.119726 24250214
40. Joel S The clinical pharmacology of etoposide: an update Cancer Treat Rev 1996 22 179 221 10.1016/S0305-7372(96)90002-X 8841390
41. Dorato MA Engelhardt JA The no-observed-adverse-effect-level in drug safety evaluations: use, issues, and definition(s) Reg Toxicol Pharmacol 2005 42 265 274 10.1016/j.yrtph.2005.05.004
42. Slevin ML The clinical pharmacology of etoposide Cancer 1991 67 1 Suppl 319 329 10.1002/1097-0142(19910101)67:1+ 3.0.CO;2-D 1984835
43. Bucar S Goncalves A Rocha E Barros A Sousa M Sá R DNA fragmentation in human sperm after magnetic-activated cell sorting J Assist Reprod Genet 2015 32 147 154 10.1007/s10815-014-0370-5 25374393
44. Sá R Cunha M Rocha E Barros A Sousa M Sperm DNA fragmentation is related to sperm morphological staining patterns Reprod BioMedicine Online 2015 31 506 515 10.1016/j.rbmo.2015.06.019
45. Valavanidis A Vlachogianni T Fiotakis C 8-hydroxy-2′-deoxyguanosine (8-OHdG): a critical biomarker of oxidative stress and carcinogenesis J Environ Sci Health, Part C 2009 27 120 139 10.1080/10590500902885684
46. Vorilhon S Brugnon F Kocer A DEollet S Bourgne C Berger M Accuracy of human sperm DNA oxidation quantification and threshold determination using an 8-OHdG immuno-detection assay Hum Reprod 2018 33 553 562 10.1093/humrep/dey038 29579272
47. Siegel R DeSantis C Virgo K Stein K Mariotto A Smith T Cancer treatment and survivorship statistics, 2012 CA Cancer J Clin 2012 62 220 241 10.3322/caac.21149 22700443
48. Magelssen H Brydoy M Fossa SD The effects of cancer and cancer treatments on male reproductive function Nat Clin Pract Urol 2006 3 312 322 10.1038/ncpuro0508 16763643
49. Tournaye H Dohle GR Barratt CLR Fertility preservation in men with cancer Lancet 2014 384 1295 1301 10.1016/S0140-6736(14)60495-5 25283570
50. Dhouib IE Jallouli M Annabi A Gharbi N Elfazaa S Lasram MM A minireview on N-acetylcysteine: an old drug with new approaches Life Sci 2016 151 359 363 10.1016/j.lfs.2016.03.003 26946308
51. Liu M Pelling JC Ju J Chu E Brash DE Antioxidant action via p53-mediated apoptosis Cancer Res 1998 58 1723 1729 9563490
52. Lohrke B Xu J Weitzel JM Krüger B Goldammer T Viergutz T N-acetylcysteine impairs survival of luteal cells through mitochondrial dysfunction Cytometry Part A 2010 77 310 320 10.1002/cyto.a.20873
53. Sagara J Bannai S Shikano N Makino N Conflicting effects of N-acetylcysteine on purified neurons derived from rat cortical culture Neuroreport 2010 21 416 421 10.1097/WNR.0b013e328337765c 20838280
54. Meistrich ML Male gonadal toxicity Pediatr Blood Cancer 2009 53 261 266 10.1002/pbc.22004 19326418
55. Zini A Gabriel MS Baazeem A Antioxidants and sperm DNA damage: a clinical perpective J Assist Reprod Genet 2009 26 427 432 10.1007/s10815-009-9343-5 19768529
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.